Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)
Status:
Terminated
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if lenalidomide and darbepoetin alfa
given together will help to control the need for transfusions in patients with low to
intermediate risk Myelodysplastic Syndrome (MDS). The safety of this combination will also be
studied.